Business Description
Titan Pharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US8883143096
Description
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.3 | |||||
9-Day RSI | 59.62 | |||||
14-Day RSI | 55.59 | |||||
3-1 Month Momentum % | -16.32 | |||||
6-1 Month Momentum % | -9 | |||||
12-1 Month Momentum % | -30.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History |
|---|
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-Forward-Revenue | 68.41 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TTNP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Titan Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.95 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -0.78 | ||
| 3-Year Sortino Ratio | -1.05 | ||
| Volatility % | 52.72 | ||
| 14-Day RSI | 55.59 | ||
| 14-Day ATR ($) | 0.283175 | ||
| 20-Day SMA ($) | 4.303655 | ||
| 12-1 Month Momentum % | -30.54 | ||
| 52-Week Range ($) | 3.03 - 5.76 | ||
| Shares Outstanding (Mil) | 1.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Titan Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Titan Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-14 | In 28 days | ||
| General meeting for 2026 | 2026-06-16 09:00 | 4.61 (-3.96%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 4.61 (-3.96%) | ||
| Annual report for 2025 | 2026-03-20 | 4.61 (-3.96%) | ||
| Third quarter earnings results for 2025 | 2026-01-02 | 4.61 (-3.96%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 4.93 (+0.20%) | ||
| General meeting for 2025 | 2025-06-16 09:00 | 4.45 (-1.98%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 4.55 (-9.00%) | ||
| Annual report for 2024 | 2025-03-20 | 3.66 (-1.08%) | ||
| Third quarter earnings results for 2024 | 2025-01-03 | 3.19 (-2.15%) |
Show
Entries
Titan Pharmaceuticals Inc Frequently Asked Questions
What is Titan Pharmaceuticals Inc(TTNP)'s stock price today?
The current price of TTNP is $4.61. The 52 week high of TTNP is $5.76 and 52 week low is $3.03.
When is next earnings date of Titan Pharmaceuticals Inc(TTNP)?
The next earnings date of Titan Pharmaceuticals Inc(TTNP) is 2026-08-14 Est..
Does Titan Pharmaceuticals Inc(TTNP) pay dividends? If so, how much?
Titan Pharmaceuticals Inc(TTNP) does not pay dividend.
Guru Commentaries on NAS:TTNP
No articles.
Press Release
Articles on Titan Pharmaceuticals Inc
No articles.